Lipocine Inc.
LPCN- 交易所
- Nasdaq
- 產業
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
近 90 天,Lipocine Inc. 內部人申報 3 筆公開市場買進、0 筆賣出;2026 年第 2 季末有 37 家機構在 13F 申報持有,市值合計 $763.2 萬;沒有大師持有。
SEC 申報
Lipocine Inc. 向 SEC 申報的 10-K、10-Q、8-K、20-F、40-F,最新的在前。
Livermore 只列出每份申報的表單、8-K 的 Item 與日期。內文請到 SEC 網站讀;8-K 的新聞稿等附件(例如 Item 2.02 的 EX-99.1)在申報目錄裡。
| 申報日 | 表單 | 8-K 的 Item | 期間 | 原文 | 申報目錄 |
|---|---|---|---|---|---|
| 2026/11/10 | 8-K | 8.019.01 | 2026/11/10 | SEC | 目錄 |
| 2026/11/5 | 8-K | 2.029.01 | 2026/11/5 | SEC | 目錄 |
| 2026/11/5 | 10-Q | – | 2026/9/30 | SEC | 目錄 |
| 2026/10/20 | 8-K | 8.019.01 | 2026/10/20 | SEC | 目錄 |
| 2026/10/7 | 8-K | 8.019.01 | 2026/10/7 | SEC | 目錄 |
| 2026/9/16 | 8-K | 8.019.01 | 2026/9/16 | SEC | 目錄 |
| 2026/9/14 | 8-K | 8.019.01 | 2026/9/14 | SEC | 目錄 |
| 2026/9/11 | 8-K | 8.01 | 2026/9/8 | SEC | 目錄 |
| 2026/9/10 | 8-K | 8.019.01 | 2026/9/10 | SEC | 目錄 |
| 2026/8/21 | 8-K/A | 5.02 | 2026/8/3 | SEC | 目錄 |
| 2026/8/4 | 8-K | 2.029.01 | 2026/8/4 | SEC | 目錄 |
| 2026/8/4 | 10-Q | – | 2026/6/30 | SEC | 目錄 |
| 2026/8/3 | 8-K | 5.027.019.01 | 2026/8/3 | SEC | 目錄 |
| 2026/6/12 | 8-K | 8.019.01 | 2026/6/12 | SEC | 目錄 |
| 2026/6/4 | 8-K | 5.025.079.01 | 2026/6/3 | SEC | 目錄 |
| 2026/6/4 | 8-K | 8.019.01 | 2026/6/4 | SEC | 目錄 |
| 2026/5/26 | 8-K | 8.019.01 | 2026/5/26 | SEC | 目錄 |
| 2026/5/19 | 8-K | 8.019.01 | 2026/5/19 | SEC | 目錄 |
| 2026/5/18 | 8-K | 8.019.01 | 2026/5/18 | SEC | 目錄 |
| 2026/5/7 | 8-K | 8.019.01 | 2026/5/7 | SEC | 目錄 |
| 2026/5/7 | 8-K | 2.029.01 | 2026/5/7 | SEC | 目錄 |
| 2026/5/7 | 10-Q | – | 2026/3/31 | SEC | 目錄 |
| 2026/4/21 | 8-K | 5.02 | 2026/4/16 | SEC | 目錄 |
| 2026/4/2 | 8-K | 8.019.01 | 2026/4/2 | SEC | 目錄 |
| 2026/4/2 | 8-K | 8.019.01 | 2026/4/2 | SEC | 目錄 |
| 2026/3/10 | 8-K | 2.029.01 | 2026/3/10 | SEC | 目錄 |
| 2026/3/10 | 10-K | – | 2025/12/31 | SEC | 目錄 |
| 2026/3/4 | 8-K | 8.019.01 | 2026/2/26 | SEC | 目錄 |
| 2026/2/18 | 8-K | 8.019.01 | 2026/2/18 | SEC | 目錄 |
| 2026/2/18 | 8-K | 2.027.018.019.01 | 2026/2/18 | SEC | 目錄 |
| 2026/1/20 | 8-K | 8.019.01 | 2026/1/20 | SEC | 目錄 |
| 2026/1/12 | 8-K | 8.019.01 | 2026/1/12 | SEC | 目錄 |
| 2026/1/12 | 8-K | 8.019.01 | 2026/1/12 | SEC | 目錄 |
| 2025/12/16 | 8-K | 8.019.01 | 2025/12/15 | SEC | 目錄 |
| 2025/12/15 | 8-K | 5.02 | 2025/12/12 | SEC | 目錄 |
| 2025/12/11 | 8-K | 8.019.01 | 2025/12/8 | SEC | 目錄 |
| 2025/11/18 | 8-K | 8.019.01 | 2025/11/18 | SEC | 目錄 |
| 2025/11/18 | 8-K | 8.019.01 | 2025/11/18 | SEC | 目錄 |
| 2025/11/6 | 8-K | 2.029.01 | 2025/11/6 | SEC | 目錄 |
| 2025/11/6 | 10-Q | – | 2025/9/30 | SEC | 目錄 |
| 2025/11/4 | 8-K | 8.019.01 | 2025/11/4 | SEC | 目錄 |
| 2025/9/30 | 8-K | 8.019.01 | 2025/9/30 | SEC | 目錄 |
| 2025/9/26 | 8-K | 8.019.01 | 2025/9/26 | SEC | 目錄 |
| 2025/9/5 | 8-K | 8.019.01 | 2025/9/5 | SEC | 目錄 |
| 2025/9/5 | 8-K | 8.019.01 | 2025/9/5 | SEC | 目錄 |
| 2025/8/26 | 8-K | 8.019.01 | 2025/8/26 | SEC | 目錄 |
| 2025/8/5 | 8-K | 2.029.01 | 2025/8/5 | SEC | 目錄 |
| 2025/8/5 | 10-Q | – | 2025/6/30 | SEC | 目錄 |
| 2025/7/9 | 8-K | 8.019.01 | 2025/7/9 | SEC | 目錄 |
| 2025/7/2 | 8-K | 8.019.01 | 2025/7/2 | SEC | 目錄 |